N',N'-dimethyl-N-propan-2-yloxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N',N'-dimethyl-N-propan-2-yloxamide
• 化学式: C₇H₁₄N₂O₂
• 分子量: 158.2
• InChiKey: GEYFRYJWPNDRJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：SHANGHAI BLUERAY BIOPHARMA CO., LTD.

  公开号：US20210053989A1

  公开（公告）日：2021-02-25

  Disclosed in the present disclosure are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present disclosure are a preparation method for the compound, a composition comprising the compound and a use of the compound for the preparation of a medicament for the prevention and/or treatment of a disease or condition associated with abnormal SHP2 activity.

  本公开涉及一种嘧啶融合的环状化合物或其药用可接受的盐、水合物、前药、立体异构体、溶剂合物或同位素标记化合物。本公开还提供了该化合物的制备方法、包含该化合物的组合物以及该化合物用于制备与异常SHP2活性相关的疾病或病况的药物的用途。
• [EN] NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS HÉTÉROCYCLIQUES UTILES EN TANT QU'INHIBITEURS DE SHP2
  申请人：JACOBIO PHARMACEUTICALS CO LTD

  公开号：WO2017211303A1

  公开（公告）日：2017-12-14

  Provided are certain pyrazine derivatives (I) as SHP2 inhibitors which is shown as formula (I), their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided are fused heterocyclic derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.

  提供了某些吡嗪衍生物（I）作为SHP2抑制剂，其化学式如下（I），以及它们的合成和用于治疗SHP2介导的疾病。更具体地，提供了有用作为SHP2抑制剂的融合杂环衍生物，生产这类化合物的方法以及治疗SHP2介导的疾病的方法。
• Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
  申请人：BLUERAY THERAPEUTICS (SHANGHAI) CO., LTD.

  公开号：US11498930B2

  公开（公告）日：2022-11-15

  Disclosed in the present disclosure are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present disclosure are a preparation method for the compound, a composition comprising the compound and a use of the compound for the preparation of a medicament for the prevention and/or treatment of a disease or condition associated with abnormal SHP2 activity.

  本公开披露了一种嘧啶融合环状化合物或其药学上可接受的盐、水合物、原药、立体异构体、溶解物或同位素标记化合物。本公开还提供了该化合物的制备方法、包含该化合物的组合物以及该化合物用于制备预防和/或治疗与 SHP2 活性异常相关的疾病或病症的药物的用途。
• FAKTOR XIA HEMMENDE PYRIDOBENZAZEPIN- UND PYRIDOBENZAZOCIN-DERIVATE
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3197891A1

  公开（公告）日：2017-08-02
• SUBSTITUIERTE OXOPYRIDIN-DERIVATE
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3197896A1

  公开（公告）日：2017-08-02